S&P 500   3,098.92 (+0.39%)
DOW   27,733.52 (+0.15%)
QQQ   201.80 (+0.42%)
CGC   20.22 (-0.39%)
BABA   186.84 (+0.07%)
T   39.35 (-0.05%)
F   9.10 (+0.22%)
ACB   3.68 (+1.66%)
BAC   33.26 (+0.24%)
DIS   138.73 (+1.46%)
S&P 500   3,098.92 (+0.39%)
DOW   27,733.52 (+0.15%)
QQQ   201.80 (+0.42%)
CGC   20.22 (-0.39%)
BABA   186.84 (+0.07%)
T   39.35 (-0.05%)
F   9.10 (+0.22%)
ACB   3.68 (+1.66%)
BAC   33.26 (+0.24%)
DIS   138.73 (+1.46%)
Log in

Calithera Biosciences Stock Price, Forecast & Analysis (NASDAQ:CALA)

$3.25
+0.10 (+3.17 %)
(As of 11/12/2019 11:04 AM ET)
Today's Range
$3.19
Now: $3.25
$3.25
50-Day Range
$2.51
MA: $2.98
$3.88
52-Week Range
$2.45
Now: $3.25
$6.90
Volume824 shs
Average Volume390,383 shs
Market Capitalization$174.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.25 million
Book Value$3.32 per share

Profitability

Net Income$-54,630,000.00

Miscellaneous

Employees79
Market Cap$174.75 million
Next Earnings Date11/12/2019 (Confirmed)
OptionableOptionable

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.


Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) posted its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.18. View Calithera Biosciences' Earnings History.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Calithera Biosciences.

What price target have analysts set for CALA?

2 brokerages have issued twelve-month price objectives for Calithera Biosciences' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Calithera Biosciences' stock price to reach $8.00 in the next year. This suggests a possible upside of 146.2% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.

What is the consensus analysts' recommendation for Calithera Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.

Has Calithera Biosciences been receiving favorable news coverage?

Media stories about CALA stock have trended very negative on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Calithera Biosciences earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Calithera Biosciences.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,810,000 shares, an increase of 21.5% from the September 30th total of 1,490,000 shares. Based on an average daily volume of 323,400 shares, the days-to-cover ratio is currently 5.6 days. Approximately 5.2% of the shares of the stock are sold short. View Calithera Biosciences' Current Options Chain.

Who are some of Calithera Biosciences' key competitors?

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and Synergy Pharmaceuticals (SGYP).

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the folowing people:
  • Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)
  • Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)
  • Dr. Keith Orford, Chief Medical Officer (Age 47)
  • Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)
  • Ms. Jennifer McNealey, VP of Investor Relations & Strategy

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhumbline Advisers (0.11%), Grimes & Company Inc. (0.04%), Wedbush Securities Inc. (0.03%) and Assenagon Asset Management S.A. (0.02%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Susan Molineaux and Value Fund L P Biotechnology. View Institutional Ownership Trends for Calithera Biosciences.

Which major investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Calithera Biosciences.

Which major investors are buying Calithera Biosciences stock?

CALA stock was bought by a variety of institutional investors in the last quarter, including Grimes & Company Inc., Wedbush Securities Inc. and Rhumbline Advisers. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, Susan Molineaux and Value Fund L P Biotechnology. View Insider Buying and Selling for Calithera Biosciences.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $3.25.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $174.75 million and generates $22.25 million in revenue each year. The biotechnology company earns $-54,630,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe.View Additional Information About Calithera Biosciences.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is http://www.calithera.com/.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]


MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  504
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Featured Article: Market Timing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel